Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats

Abstract

The present study provides substantial information that demonstrates that long-term selective AII blockade by irbesartan improves insulin signaling and is associated with decreased insulin receptor Ser994 phosphorylation in the liver of a representative animal model of the human metabolic syndrome.